Ripretinib TKI Coverage for Mutation-Resistant GIST
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for gastrointestinal stromal tumors (GIST) are inadequate for patients with imatinib-resistant mutations, particularly those with secondary mutations in KIT exons 13, 14, 17, and PDGFRA exons 14 and 18, leading to drug resistance and limited efficacy.
Innovation Solution
Administration of ripretinib, a tyrosine kinase inhibitor, in various dosages and formulations to treat advanced GISTs, including patients intolerant or resistant to previous TKIs like imatinib, sunitinib, and regorafenib, targeting a broad spectrum of KIT and PDGFRA mutations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If imatinib is used to treat GIST, then patients with KIT exon 11 mutations achieve good response, but patients with secondary mutations in KIT exons 13, 14, 17 and PDGFRA exons 14 and 18 develop drug resistance
Solution Approach 1:
Ripretinib is designed as a universal TKI that can inhibit multiple KIT and PDGFRA mutation types simultaneously. The compound demonstrates broad-spectrum activity against KIT exon 9, 11, 13, 14, 17 mutations and PDGFRA exon 12, 14, 18 mutations, making it applicable to diverse GIST patient populations with different mutational profiles
Solution Approach 2:
The invention changes the chemical structure parameters of TKIs to create ripretinib with modified binding characteristics. This structural optimization enables the drug to maintain effective inhibition across multiple mutation types that previously resisted imatinib, particularly addressing the adaptability issue through parameter optimization
2Reliability
If sunitinib is used as second-line therapy, then some imatinib-resistant patients benefit, but progression-free survival remains limited at median 4.2 months
Solution Approach 1:
Ripretinib employs optimized pharmacokinetic parameters including sustained plasma concentration maintenance and appropriate half-life characteristics. These parameter changes enable longer duration of effective drug exposure, contributing to extended progression-free survival of 6.3 months compared to sunitinib's 4.2 months
Solution Approach 2:
The dosing regimen and pharmacokinetic profile of ripretinib are designed to maintain continuous therapeutic concentrations in the bloodstream. This continuity of useful action ensures sustained tumor cell inhibition over the dosing interval, preventing tumor regrowth and extending the duration of response
3Reliability
If regorafenib is used as third-line therapy, then patients experience median PFS of 2.8 months, but adverse events including palmar-plantar erythrodysesthesia syndrome occur
Solution Approach 1:
Ripretinib utilizes optimized dosing parameters and pharmacokinetic characteristics to achieve effective tumor inhibition at lower exposure levels. This parameter optimization allows for reduced dosing intensity compared to regorafenib, thereby minimizing adverse events while maintaining treatment efficacy
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.